BML Inc

BML Inc maintains a strong liquidity position with a current ratio of 2.72 and a cash and equivalents balance of ¥67.56 billion, which represents 38% of total assets. The company's liquidity_fpt score indicates a low liquidity risk, supported by a debt-to-equity ratio of 0.05, suggesting minimal leverage pressure. Profitability metrics show a return on equity (ROE) of 4.84% and a return on assets (ROA) of 3.53%, both below the industry median for healthcare providers. The operating margin of 6.33% (calculated from operating income of ¥9.07 billion on revenue of ¥143.19 billion) is also below the sector average, indicating room for improvement in cost management and pricing power. Geographically, BML Inc's revenue is concentrated in Japan, with no disclosed international operations. The company's business is entirely within the pharmaceuticals segment, with no diversification across therapeutic areas or product lines. This concentration increases exposure to domestic regulatory shifts and pricing pressures. Looking ahead, BML Inc is projected to grow revenue by 3.5% in the current fiscal year and 2.8% in the next, based on analyst estimates and historical performance. However, the free cash flow remains negative at -¥5.94 billion, driven by capital expenditures of -¥16.66 billion, which may constrain reinvestment or shareholder returns. The risk assessment indicates low dilution and liquidity risks, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial distress risk. However, the negative free cash flow and high capital expenditures suggest potential reinvestment pressures or funding needs in the near term. Recent filings and transcripts show no material changes in business strategy or financial outlook. Analysts have issued a single "Hold" recommendation with a mean price target of ¥4,500, indicating a neutral stance on valuation.